You are here

Big Pharma losing price leverage amid squeeze by payers

Latest quarterly results raise pressure on drugmakers to pump up sales volumes, find lucrative new treatments

Executives from Mylan NV, the maker of allergy shot EpiPen, and Valeant Pharmaceuticals International Inc were brought before Congress to explain what they charge.

New York

BEING a big drug company isn't what it used to be.

The largest drugmakers are finding it more difficult to charge high prices for a range of medications, their latest quarterly results show. That's raising the pressure to pump up sales volumes and find lucrative new...

Market voices on: